PTC Therapeutics, Inc. has promoted Emily Hill to chief financial officer. Ms. Hill joined the company in November 2013 and was most recently senior vice president and head of Investor Relations.

Prior to joining PTC Therapeutics, Emily was director of Investor Relations of Warner Chilcott where she was responsible for leading the function. Additionally, Ms. Hill was senior manager of Investor Relations at Genzyme Corp. Prior to Genzyme, she was a Biotech Equity Research Associate at Summer Street Partners.

“It is my pleasure to announce Emily’s promotion to CFO,” said Stuart W. Peltz, Ph.D., chief executive officer of PTC Therapeutics, Inc. “Emily has a deep knowledge of our industry and has strong relationships and understanding of the investor community.  Emily has a great track record of leadership at PTC and will be part of the executive team to deliver value to patients and shareholders as we continue to realize our vision of bringing more treatments to patients living with rare disorders.”